Merck & Co's Frazier: International Business Is Only Scratching The Surface

Merck & Co’s sales and EPS grow by double digits in the first quarter, with the performance of Keytruda, and growth in non-US markets, a feature of the three months.  

Great Wall
China, and other international markets, are important growth markets for Merck & Co. • Source: Shutterstock

Merck & Co. Inc.’s sales in China grew by 58% to $275m in the 2019 first quarter, or by 67% excluding the negative impact from foreign exchange. That double-digit growth, led by newly launched products, prompted chairman and CEO Ken Frazier to highlight the beneficial effects of non-US markets on the company’s business.

“Our international business, which represented nearly 60% of our sales this quarter, has strong momentum, and we believe we have...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.